





CFORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-144 CIP		SERIAL NO. 09/934,060	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT DeVico et al.			
				FILING DATE August 21, 2001		GROUP 1648 Not Yet Assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AC	AA	5,420,030	May 30, 1995	Reitz, Jr. et al.	435	235.1	
	AB	5,576,000	Nov 19, 1996	Reitz, Jr. et al.	424	188.1	
	AC	5,689,313	Nov 18, 1997	Sotheran	348	715	
	AD	5,518,723	May 21, 1996	DeVico et al.	424	196.11	
	AE	5,843,454	Dec 1, 1998	DeVico et al.	424	196.11	
	AF	5,871,913	Feb 16, 1999	Maddon et al.	435	6	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on Page 2							
EXAMINER <i>John White</i>					DATE CONSIDERED 11/10/03		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

11/10/03

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-144 CIP		SERIAL NO. 09/934,060	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT DeVico et al.			
				FILING DATE August 21, 2001		GROUP 1648 Not Yet Assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
							APR 09 2002
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION NO
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	°AH	R.A. Kaup et al., "Shutting down HIV," Nature, 370; 416 (1994)					
	°AI	R.A. Kaup et al., "Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome," Journal of Virol, 68; 4650-4655 (1994)					
	°AJ	E.A. Emini, et al., "Prevention of HIB-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody," Nature, 355; 728-739 (1992)					
	°AK	R. Shibata et al., "Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys," Nature Medicine, 5; 204-210 (1999)					
	°AL	M.C. Gauduin et al., "Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1," Nature Medicine, 3; 1389-1393 (1997)					
	°AM	P.W. Parren et al., "Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site," AIDS, 9; F1-F6 (1995)					
	°AN	J.W. Eichberg et al., "Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG," AIDS Res. Hum. Retroviruses, 8; 1515 (1992)					
	°AO	R.H. Ward et al., "Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin," Nature, 352; 434-436 (1991)					
	°AP	J.L. Heeney et al., "Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques," Proc. Nat. Acad. Sci. U.S.A., 95; 10803-10808 (1998)					
	°AQ	Mascola et al., "Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies," Jour. Of Virol., 73; 4009-4018 (1999)					
	°AR	J.P. Moore et al., "HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells," AIDS, 9; S117-S136 (1995)					
	°AS	Q.J. Sattentau, "Neutralization of HIV01 by antibody," Curr. Opin. Immun., 8; 540-545 (1996)					
	°AT	R. Wyatt et al., "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens," Science, 280; 1884-1888 (1998)					
EXAMINER 					DATE CONSIDERED 11/10/03		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-144 CIP		SERIAL NO. 09/934,060	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) 				APPLICANT DeVico et al.		GROUP 1698	
				FILING DATE August 21, 2001		Not Yet Assigned	
				U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	AU	"Claudio Vita. "Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein." PNAS, November 9, 1999, vol. 96, no. 23, patent. 13091-13096.					
EXAMINER				DATE CONSIDERED			
				11/10/03			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							



FEB 19 2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.